NCT04797286View on ClinicalTrials.gov

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
SclerodermaMildly Elevated Pulmonary Pressures
Interventions
DRUG

Sildenafil

Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.

OTHER

Placebo

Oral pill placebo.

Trial Locations (2)

21287

RECRUITING

Johns Hopkins, Baltimore

70806

NOT_YET_RECRUITING

Louisiana State University, New Orleans

All Listed Sponsors
collaborator

Louisiana State University Health Sciences Center in New Orleans

OTHER

collaborator

United States Department of Defense

FED

lead

Johns Hopkins University

OTHER